Paid $710 million upfront in 2014Chief operating officer Scott Smith said: "Crohn's disease is a debilitating condition with few effective long-term treatment options. While we are disappointed with the results of REVOLVE, we remain committed to advancing our portfolio of novel medicines for patients suffering from this disease and other inflammatory bowel disorders."
Inflammatory disease portfolio - ozanimodCelgene said that at the World Congress of Gastroenterology meeting this month, two-year data from the Phase II TOUCHSTONE trial of ozanimod in UC and Phase II data from the STEPSTONE trial in CD were presented.
Otezla in UCIt also singled out Otezla (apremilast). It said a randomised controlled Phase II trial (UC-001) in UC is ongoing, with data expected by the end of the year. Pending positive results, a broad Phase III UC programme could begin in 2018.
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.